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Abstract
Background: Pioglitazone was reported to improve hepatic steatosis and necroinflammation in
human studies. To investigate whether the hepato-protective effect of pioglitazone was associated
with an improvement of antioxidant defense mechanism, oxidative DNA damage and repair activity
were determined in a high fat diet model. Male C57BL/6 mice were respectively fed with a 30% fat
diet, the same diet with pioglitazone 100 mg/kg/day, or a chow diet as control for 8 weeks. Tissue
oxidative stress was indicated by malondialdehyde concentration. Oxidative DNA damage was
detected by immunohistochemical 8-oxoG staining. Enzymatic antioxidant defense was detected by
the real-time PCR of superoxide dismutase (Sod1, Sod2) and DNA glycosylase (Ogg1, MutY).
Oxidative DNA repair was detected by immunohistochemical staining and western blotting of
OGG1 expression.
Results: Our results show that hepatic steatosis was induced by a high-fat diet and improved by
adding pioglitazone. Malondialdehyde concentration and 8-oxoG staining were strongly increased
in the high-fat diet group, but attenuated by pioglitazone. Gene expressions of antioxidant defense
mechanism:  Sod1, Sod2, Ogg1 and MutY significantly decreased in the high-fat diet group but
reversed by pioglitazone co-administration.
Conclusion: The attenuation of hepatic oxidative DNA damage by pioglitazone in a high-fat diet
may be mediated by up-regulation of the antioxidant defense mechanism and oxidative DNA repair
activity. The diminution of oxidative damage may explain the clinical benefit of pioglitazone
treatment in patients with non-alcoholic fatty liver disease.
Background
The prevalence of non-alcoholic fatty liver disease
(NAFLD) in the general population is estimated to be
between 14–24% in wealthy countries. NAFLD presents
as a hepatic manifestation of metabolic syndrome and is
characterized by triglyceride accumulation, lobular
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necroinflammation, and may progress to fibrosis, cirrho-
sis and hepatocellular carcinoma. Recently, NAFLD has
been speculated to be initiated by insulin resistance [1,2].
Some investigations have demonstrated that reactive oxy-
gen species (ROS) production increases during insulin
resistance and then triggers lipid peroxidation, mitochon-
drial dysfunction and releasing of several cytokines, such
as tumor necrosis factor-α (TNF-α) [3,4]. In human stud-
ies, it has been shown that a high-fat diet increases the
hepatocellular free fatty acid pool and increases ROS for-
mation in mitochondria. Furthermore, ROS directly dam-
age mitochondrial DNA and trigger the progression of
simple steatosis to steatohepatitis, fibrosis, cirrhosis and
possible formation of hepatocelluar carcinoma [3-6].
Among various threats to living cells, ROS injury to DNA
is as a result of cellular respiration, metabolism, and envi-
ronmental insults. Damaged mitochondria are the major
source of ROS production and go into a vicious cycle of
increasing DNA damage by the ROS. ROS can damage cel-
lular DNA directly by causing strand breaks and base oxi-
dation in DNA [7,8]. Physiologically, defense mechanism
against oxidative stress includes antioxidant defense and
repair mechanism. Superoxide dismutases (SOD1 and
SOD2) represent a family of enzymatic antioxidant
defense involved in converting superoxide into peroxide.
Sod1 encodes cytosolic SOD and Sod2 encodes mitochon-
drial SOD, which is more important antioxidant defense
than Sod1 to prevent ROS production in the mitochondria
[9,10]. Mitochondrial DNA is more prone to oxidative
damage than nuclear DNA. The most common oxidation
product of DNA, 7,8-dihydro-8-oxoguanine (8-oxoG), is
particularly abundant and stable with approximately
~180 guanines oxidized to 8-oxoG per mammalian cell
per day. On the contrary, base excision repair (BER) is the
major repair system allowing mitochondria to efficiently
repair oxidized DNA bases such as 8-oxoG. BER, initiated
by 8-oxoG glycosylase (OGG1) and cooperated by MutY
homolog DNA glycosylase (MutY), is the most important
defense against 8-oxoG mutation in mitochondria [11]
The Ogg1 gene encodes DNA 8-oxoG glycosylase which
recognizes and removes 8-oxoG from DNA. MutY
homolog DNA glycosylase (MutY) is another monofunc-
tional glycosylase, which specifically excises adenine mis-
incoporated opposite 8-oxoG in the mismatch repair
(MMR) system against oxidative stress. Evidence has
shown OGG1 and MutY form a cooperative defense
against G: C to T: A transversions [11-14]. Thus, Ogg1 and
MutY gene expression represents oxidative repair activity
of DNA.
Pioglitazone, a derivative of thiazolidinedione (TZD), is a
peroxisome proliferator-activated receptor-γ (PPARγ) ago-
nist that is used to treat type 2 diabetes by increasing insu-
lin sensitivity. In subjects with NAFLD, insulin resistance
is associated with hyperinsulinemia, hyperglycemia, high
plasma free fatty acid, and low plasma adiponectin levels.
TZDs may reverse these abnormalities in NAFLD subjects
[3,5,15,16]. More recently, a placebo-controlled trial in
subjects with nonalcoholic steatohepatitis (NASH)
showed significant improvement of histological features
occurred in subjects receiving pioglitazone as compared
with placebo group [17]. Reduction of the insulin resist-
ance is generally thought to be the mechanism of TZD
treatment in NAFLD [2]. In addition, oxidative stress has
been demonstrated as a causal role in insulin resistance
and TZDs is reported to reduce vascular oxidative stress
[18]. Therefore, it is intriguing to identify whether the
hepato-protective mechanism of TZDs is mediated by
attenuating the hepatic oxidative DNA damage. In a mice
model of high fat diet, we investigated the changes of oxi-
dative stress, indicated by malondialdehyde (MDA) and
oxidative DNA damage, indicated by 8-oxoG. We further
explored up-regulation of the antioxidant defense and
repair genes (SOD1, SOD2, OGG1 and MutY) by pioglita-
zone and investigated the improvement of hepatic steato-
sis by reversal of the oxidative stress and damage.
Methods
Male C57BL/6 inbred mice, aged 8 weeks, were obtained
from BioLASCO Technology (Charles River Taiwan Ltd).
All mice received standard animal care under the supervi-
sion of our Institutional Animal Care and Use Committee.
The mice were caged in an air-conditioned animal facility
at 23°C on a 12-h light: dark cycle and were maintained
with free access to water and food. All the mice were fed
with standard chow diet (Basal diet™ 5755, PMI Nutrition
International, St. Louis, MO, USA) for one week. The com-
position of this basal chow diet was 60.6% (wt/wt) carbo-
hydrate (starch 43.6% and sucrose 16.9%), 10% fat, 19%
protein, 4.3% fiber, 5% mineral mixture and 0.2% vita-
min mixture. They were then divided into three groups:
(1) chow diet (n = 5); (2) high-fat diet (30%) (n = 5) (cat-
alog #7166, PMI Nutrition International, Saint Louis,
MO, USA); (3) high-fat diet and gastric gavage with piogl-
itazone 100 mg/kg/day (n = 5). The high-fat diet, based
on basal diet 5755 (contained 40.6% carbohydrate (dex-
trin 23.6% and sucrose 15%), 15% corn oil, 15% lard,
19% protein, 4.3% fiber, 5% mineral mixture and 0.2%
vitamin mixture) provided 53.1% of calories from corn
oil and lard. Pioglitazone was kindly provided by Takeda
Chemical Industries (Taiwan), Ltd. Animals were fed in
these groups for 8 weeks prior to euthanasia.
Biochemical analysis
Throughout the experiment, body weight was recorded
daily. At the end of experiment, the animals were sacri-
ficed after an overnight fast. They were euthanized by
intraperitoneal injection of the anaesthetic Zoletil (10
mg/kg) (Virbac, Carros, France). Blood samples were col-BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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lected from the heart at the time of sacrifice for measure-
ment of plasma glucose, serum cholesterol, triglyceride
and alanine aminotransferase. These parameters were
assessed using an autoanalyser (Roche Diagnostics, Tai-
pei, Taiwan). After rinsing with phosphate buffered saline
(PBS), the livers were immediately cut into pieces on ice.
Two pieces of liver were fresh-frozen in liquid nitrogen for
storage at -80°C for measurement of hepatic triglyceride
content and subsequent RNA isolation. Hepatic lipids
were extracted from tissue with chloroform/methanol
(2:1, vol/vol) and centrifugation. Then, the supernant was
subsequently analyzed for TG content by colorimetric
enzymatic hydrolysis (Triglyceride GPO-Triginder rea-
gent; Sigma, St. Louis, MO). The remaining liver samples,
fixed with 4% paraformaldehyde and embedded in paraf-
fin, were prepared for morphological and immunohisto-
chemical analyses. Thiobarbituric acid reactive substances
(TBARS) assay was used to measure the tissue concentra-
tion of malondialdehyde (MDA), which is a product of
lipid peroxidation, as an indicator of oxidative stress (Zep-
toMetrix, Co, NewYork).
Histologic and immunohistochemical analysis
The dissected liver specimens were fresh-frozen and fixed
in Tissue-TekR O.C.T compound (Sakura Finetechnical
Co., Tokyo, Japan) for oil-red O staining. Other parts of
the dissected specimens were embedded in paraffin for
hematoxylin and eosin (H&E) and Masson trichrome
staining. Some sections of liver were processed and incu-
bated with a mouse primary monoclonal antibody for 8-
hydroxyguanosine (diluted 1:2000 in PBS, pH 7.4) or rab-
bit anti-mouse OGG1 (1: 2000 in PBS, pH 7.5) (Alpha
Diagnostic Intl. Inc., San Antonio, TX, USA) overnight at
4°C. The pretreated slides were stained with reagents from
a commercially available kit applying a streptavidin-HRP
method with 3, 3-diaminobenzamide (DAB) as a chro-
mogen (DAKO Corporation, Carpinteria, CA, USA). Nor-
mal mouse serum was substituted for the primary
antibody as negative control. Then, the slides were coun-
terstained with hematoxylin and examined under light
microscopy. The histologic scoring system validated by
the Pathology Committee of the NASH Clinical Research
Network for human was applied for semi-quantitative
evaluation of these liver specimens of mice. The histologic
features of activity score included sum of steatosis (0–3),
lobular inflammation (0–2), hepatocellular ballooning
(0–2) and fibrosis (0–4) [19]. The immunostaining inten-
sity of 8-oxoG and OGG1 were graded according to the
following score: "0"= no staining, "1" = weak staining,
"2"= moderate staining, "3"= strong staining. The histo-
logic grading and intensity of immunostaining were eval-
uated of 10 fields in high magnification (400×) of each
group by one hepatologist and one pathologist who had
no idea of the sources of the sections.
Real-time PCR (RT-PCR) for genes related to oxidative 
defense mechansim
Total hepatic RNA was extracted using Trizol reagent
according to the supplier's protocol, with absorbancy
measured at 260 nm. Briefly, 1 μg of total RNA was used
to synthesize first-strand cDNAs with an iScript™ cDNA
Synthesis Kit (Bio-Rad Laboratories, INC., CA, USA).
Then, the first-strand cDNA was diluted with water in a
ratio of 1:9, and the aliquots were processed to amplify
the genes related to oxidative defense mechanism (Sod1,
Sod2, Ogg1 and MutY) and β-actin cDNA fragments with
iQ™ SYBR Green Supermix (Bio-Rad Laboratories, INC.,
CA, USA). RT-PCR was performed in a Bio-Rad MiniOpti-
con Real-Time PCR System (Bio-Rad Laboratories, INC.,
CA, USA). The primers used for RT-PCR were purchased
from Bio Basic Inc. (Ontario, Canada). The primer
sequences were listed in table 1.
Western blot analysis
OGG1 expression in liver was determined with Western
blot analysis. Thirty micrograms of protein was separated
on a 10% SDS-polyacrylamide gel running with constant
current for 2.5 hrs. After electrophoresis, the proteins were
transferred to PVDF membrane (Millipore, Bedford, M.A,
USA), assembled in a Bio-Rad Transblot and immersed in
blocking buffer overnight at 4°C. Then, the membrane
was used to detect the levels of mouse OGG1 protein with
a primary antibody against mouse OGG1 (Alpha Diag-
nostics Intl. Inc., San Antonio, TX, USA) or β-actin (Alpha
Diagnostics Intl. Inc., San Antonio, TX, USA) as a control.
Immune complexes were visualized using ECL plus detec-
tion reagents (Amersham International, NJ, USA). Quan-
titative comparison of the fluorescent images was
achieved with a densitometer.
Table 1: Primer sequences of genes involved in antioxidant 
defense and DNA repair
Gene Sequence Gene ID number
Sod1 F: 5'-gcggtgaaccagttgtgttgtc-3' NM_011434
R: 5'-cagtcacattgcccaggtctcc-3'
Sod 2 F: 5'-atgttacaactcaggtcgctcttc-3' NM_013671
R: 5'-tgatagcctccagcaactctcc-3'
Ogg1 F: 5'-gtgactacggctggcatcc-3' NM_010957
R: 5'-aggcttggttggcgaagg-3'
MutY F: 5'-cattgcttccatcgcctttgac-3' NM_133250
R: 5'-gctaagttccagaggtgatgagag-3'
Beta-actin F: 5'-gaaatcgtgcgtgacatc-3' NM_007393
R: 5'-ccatacccaagaaggaagg-3'
Ogg1: codes for oxoguanine DNA glycosylase
MutY: codes for MutY homolog DNA (A/G specific adenine) 
glycosylase
Sod1, codes for cytosolic superoxide dismutase; Sod2, codes for 
mitochondrial superoxide dismutase.
Beta-actin as a competitive controlBMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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Statistical analysis
All statistical analyses were performed using SPSS 10.0 for
Windows (SPSS Inc., Chicago, IL, USA). Values are pre-
sented as mean ± S.E. Statistical significance was deter-
mined as p < 0.05 using non-parametric Kruskal-Wallis
test among three groups or Wilcoxon rank-sum tests
between two groups.
Results
In this study, biochemical data of three groups are shown
in table 2. Body weight gain increased significantly in
group of high fat diet plus pioglitazone than groups of
chow diet or high fat diet. Fasting blood glucose, serum
cholesterol and hepatic triglyceride content were signifi-
cantly different among three groups, especially higher in
groups of high fat diet than the other two groups. Tissue
oxidative stress, indicated by MDA concentration, was sig-
nificantly higher in high fat diet group and reversed mark-
edly by co-administration with pioglitazone.
As compared to control mice (A and D in Figure 1), the
hematoxylin-eosin staining and oil-red O staining
showed larger and more lipid droplet accumulation in
liver parenchyma in high-fat diet group (B and E in Figure
1, respectively). Hepatic steatosis was improved by piogl-
itazone co-administration (C and F in Figure 1, respec-
tively) with smaller lipid droplets than those of high fat
group. The activity score of the histopathologic grading,
shown in chow diet (3.75 ± 0.96), high fat diet (6.0 ±
0.82) and high fat diet adding pioglitazone (4.0 ± 1.91),
was significantly different among three groups (p < 0.05,
Kruskal-Wallis test). There was no obvious fibrosis identi-
fied by Masson trichrome stain among three groups (not
shown). However, the improvement of steatosis, necroin-
flammation and liver cell ballooning by adding pioglita-
zone was also confirmed by the semi-quantitative scoring
system.
Oxidative DNA damage was determined with 8-oxoG
staining (Figure 2). The intensity of staining was faint
(score 0.6 ± 0.13) in chow diet group and much stronger
(score 2.81 ± 0.09) in high fat diet group. In comparison
with that of chow diet (Figure 2A), it demonstrated a
noticeable increase of 8-oxoG in hepatocytes (Figure 2B).
Pioglitazone administration in the high-fat group reduced
the intensity of 8-oxoG staining (score 1.32 ± 0.10) in
liver (Figure 2C). The intensity of 8-oxoG staining showed
significant difference among three groups (p  < 0.001,
Kruskal-Wallis test).
The immunohistochemical staining of OGG1 expression
was less apparent in the high-fat diet (staining score 0.19
± 0.09, Fig. 3B) than in chow diet group (staining score
0.67 ± 0.13, Figure 3A). Mice treated with pioglitazone
increased expression of OGG1 in hepatocytes (staining
score 2.77 ± 0.09, Figure 3C). Intensity of the OGG1 stain-
ing expressed faint in high fat diet, however, it was signif-
icantly enhanced by adding pioglitazone (p  < 0.001,
Kruskal-Wallis test).
Gene expressions of Sod1, Sod2, Ogg1 and MutY mRNA,
involved in enzymatic antioxidant defense and oxidative
DNA repair, demonstrated a parallel trend of down-regu-
lation in high fat diet but significant up-regulation by add-
ing pioglitazone (Figure 4). The mRNA expression of
Ogg1 in high-fat group declined significantly to 34% of
that in chow diet group. However, it was significantly up-
regulated to 1.36-fold of the chow diet group and 4-times
of the high-fat diet group by co-administration of piogli-
tazone. Western blotting analysis for OGG1 demonstrated
a similar trend with the expression of OGG1 mRNA. The
OGG1 protein expression revealed a substantial decrease
in high fat diet and retrieved significantly by pioglitazone
co-administration compared with the high fat diet group
alone (Figure 5).
Discussion
Our study clearly demonstrated that oxidative DNA dam-
age is increased in a steatotic liver of mice fed with a high
fat diet. The oxidative DNA damage induced by a high fat
Table 2: Biochemical data of three groups
Group Chow diet (n = 5) High fat diet (n = 5) High fat diet + PioG (n = 5) P
Initial BW (gm) 21.1 ± 0.3 21.6 ± 0.4 20.8 ± 0.5 0.538
Final BW (gm) 24.8 ± 0.9 26.0 ± 0.9 27.6 ± 0.7 0.088
BW gain (gm) 3.7 ± 0.7 4.4 ± 0.8 5.0 ± 0.5 0.025
Blood glucose (mg/dl) 125.0 ± 8.0 169.2 ± 4.2 147.6 ± 7.2 0.011
Cholesterol (mg/dl) 59.5 ± 10.4 159.7 ± 37.1 151.6 ± 14.2 0.008
Triglyceride (mg/dl) 71.9 ± 17.1 102.8 ± 27.6 95.9 ± 13.0 0.355
ALT (IU/L) 14.8 ± 5.5 13.0 ± 5.9 27.7 ± 13.6 0.691
Hepatic TG (mg/g protein) 72.0 ± 19.9 177.5 ± 61.4 153.6 ± 60.9 0.023
MDA (nmol/mg protein) 5.9 ± 1.0 9.7 ± 0.8 5.5 ± 0.3 0.008
Values are mean ± S.E.
ALT: alanine aminotransferase; Hepatic TG: hepatic triglyceride content; MDA: malondialdehyde
Kruskal-Wallis test were used for statistical analysis; p < 0.05 was indicated significant.BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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Histopathology of HE stained liver sections (400×) in (A) chow diet; (B) high-fat diet; (C) high-fat diet co-administered with  pioglitazone Figure 1
Histopathology of HE stained liver sections (400×) in (A) chow diet; (B) high-fat diet; (C) high-fat diet co-
administered with pioglitazone. Histopathology of oil-red O stained liver sections (200×) in (D) chow diet; (E) high-fat 
diet; (F) high-fat diet co-administered with pioglitazone. Hepatic steatosis is strongly induced by high fat diet and improved by 
co-administration of pioglitazone.BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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diet can be attenuated by the pioglitazone treatment. Our
findings include: (1) Tissue oxidative stress was signifi-
cantly enhanced with higher MDA content and stronger 8-
oxoG staining in high fat diet, but attenuated by co-
administration of pioglitazone. (2) Gene expression of
enzymatic antioxidant defense and DNA repair mecha-
nism, including Sod1, Sod2, Ogg1 and  MutY, all were
down-regulated in high fat diet but significantly reversed
by adding pioglitazone in high fat diet.
High-fat diet and lack of exercise are causing a burden-
some epidemic of obesity, diabetes, and NAFLD. NAFLD
is characterized by triglyceride accumulation in hepato-
cytes, which probably develop steatohepatitis, fibrosis,
and even hepatocellular carcinoma formation by second-
ary hit. Although the mechanisms responsible for NAFLD
are still unclear, it may be initiated by insulin resistance.
It has been reported that insulin resistance will enhance
ROS production and oxidative stress. Then, the oxidative
stress accelerates the progression of NAFLD to steatohep-
atitis through a series of signaling cascade pathways, such
as mitogen-activated protein kinases and nuclear factor κB
[1-3,5,20]. ROS production is significantly increased in
subjects with nonalcoholic steatohepatitis and in rats fed
with high fat diet [21-23]. Chronic oxidative stress sec-
ondary to ROS overproduction and antioxidant deletion
is linked to chemically altering DNA, protein and lipids
[3,4,20,22,24]. In this study, we demonstrated that
Immunohistochemistry of hepatic 8-oxoG expression Figure 2
Immunohistochemistry of hepatic 8-oxoG expression. (A) chow diet (400×); (B) markedly increased 8-oxoG expres-
sion in hepatocytes of high fat diet (400×); (C) attenuation of the increase of 8-oxoG expression by pioglitazone administration 
with high-fat diet (400×).
Immunohistochemistry of hepatic OGG1 expression Figure 3
Immunohistochemistry of hepatic OGG1 expression. (A) basal OGG1 activity in chow diet (400×); (B) decreased 
OGG1 activity in high-fat diet (400×); (C) reversal of decreased OGG1 expression in hepatocytes co-administered high fat diet 
and pioglitazone (400×).BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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increased oxidative damage with more 8-oxo-G accumula-
tion existed in steatotic hepatocytes in mice fed a high-fat
diet. Additionally, genes expression for enzymatic antioxi-
dant defense and DNA repair mechanism (Sod1, Sod2,
Ogg1 and MutY mRNA) apparently decreased in the livers
of mice fed with high fat diet. These results apparently
prove that hepatic oxidative DNA damage was markedly
raised in accompany with diminished antioxidant defense
and repair activity in a mice model of high fat diet. This
preliminary finding implicate that high fat intake may
result in hepatic steatosis as well as accumulation of oxi-
dative DNA damage. And the depletion of antioxidant
defense and impairment of DNA repair mechanism may
contribute to the progression of NAFLD.
Normally, PPARγ is predominantly expressed in adipose
tissue and expressed at very low levels in liver. However,
in animal models of insulin resistance and fatty livers, the
hepatic expression of PPARγ is markedly increased. Possi-
bly, PPARγ activation is strongly involved in the develop-
ment of NAFLD [5,15,25-27]. Human studies have
demonstrated that TZD can reverse many abnormalities in
nonalcoholic steatohepatitis. The histological features of
steatosis, ballooning necrosis and centrilobular inflam-
mation significantly improved in subjects with nonalco-
holic steatohepatitis receiving pioglitazone treatment
compared with placebo [17,28]. Several mechanisms have
been explored to explain the hepato-protective effects of
TZDs in the treatment of NAFLD, including: amelioration
Real-time PCR for mRNA expression of genes related to enzymatic antioxidant defense and DNA repair, normalized by beta- actin Figure 4
Real-time PCR for mRNA expression of genes related to enzymatic antioxidant defense and DNA repair, nor-
malized by beta-actin. (A) Sod1. (B) Sod2. (C) Ogg1. (D) MutY. Each experiment was performed in duplicate and is repre-
sented as the mean ± S.E of five mice in each group. (a p < 0.01 compared with chow diet; b p < 0.01 compared with high fat 
diet by Wilcoxon rank-sum test).
(A)BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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of insulin resistance, increasing adiponectin concentra-
tion, reducing the TNF-α production, activation of AMP-
related protein kinase and inactivation of the intracellular
pro-inflammatory signaling pathway [4-6,29]. In an ani-
mal study, pioglitazone treatment increased the Cu, Zn-
SOD activity, decreased catalase activity and the level of
peroxidation products of liver and kidney in diabetic rab-
bit or rats induced by alloxan [30,31]. Evidence has dem-
onstrated that increased oxidative stress has recently been
recognized as an essential role in insulin resistance [18].
In this study, we demonstrated that MDA and 8-oxo-G
expression markedly increased with reciprocal decrease of
Sod1, Sod2, Ogg1 and MutY mRNA and OGG1 protein
expression in liver tissue of high fat diet. As well, the
above changes are reversed by adding pioglitazone. To our
knowledge, this is the first study to demonstrate that
pioglitazone treatment, by enhancing enzymatic antioxi-
dant defense and DNA repair mechanism, could attenuate
the hepatic oxidative stress and DNA damage induced by
high fat diet. It may indicate one of the hepato-protective
mechanisms of pioglitazone is mediated by retrieving oxi-
dative DNA repair, which in turn block the vicious cycle of
ROS production, improve insulin sensitivity and halt the
pro-inflammatory signaling transduction. However, is the
hepato-protective effect of pioglitazone due to the
improvement of insulin sensitivity, and/or due to a direct
effect of DNA repair on liver cells? This in vivo study of
dietetic model of hepatic steatosis and co-administration
with pioglitazone is limited to conclude.
In the progression of NAFLD to steatohepatitis, cirrhosis
and carcinoma, ROS plays an essential role to trigger lipid
peroxidation, induce mitochondrial dysfunction, stimu-
late cytokine release, and activate stellate cell. There is
growing evidence to show mitochondrial dysfunction
associated with ROS overproduction participate a vicious
cycle leading to worsening of NAFLD [3-5]. If the excess
ROS persists, the risk of continuous oxidative DNA dam-
age, genetic mutation and the cancer formation increases
[7-10]. In mammalian cells, there are at least two defense
pathways involved to overcome the oxidative damage
from ROS. They are enzymatic antioxidant defenses (such
as SOD, catalase) and DNA repair mechanisms (OGG1
and MutY). The vast majority of small oxidative DNA
damages, especially in mitochondria, are repaired by the
BER system. BER primarily repairs the mutation caused by
ROS generation during internal metabolism to keep
genome integrity. OGG1 is the only glycosylase for 8-
oxoG removal in mouse mitochondria and plays more
important role in mitochondria than nuclear DNA repair
[9,11-14]. Our result demonstrated the insulin sensitizer,
pioglitazone, is capable to enhance the mitochondrial
Western blotting of hepatic OGG1 expression Figure 5
Western blotting of hepatic OGG1 expression. There was a significant decrease in OGG1 expression in the high-fat diet 
compared with chow diet (a p < 0.01, Wilcoxon rank-sum test) but co-administered of pioglitazone with the high-fat diet signif-
icantly reversed the decreased OGG1 expression in comparison with that of the high-fat diet alone (b p < 0.01, Wilcoxon rank-
sum test). Each experiment was performed in duplicate and is represented as the mean ± S.E of five mice in each group.BMC Molecular Biology 2008, 9:82 http://www.biomedcentral.com/1471-2199/9/82
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antioxidant defense (Sod2) and DNA repair (Ogg1 and
MutY) system to attenuate oxidative stress and oxidative
DNA damage (cytosol 8-oxoG). This finding is consistent
with the hepatic salvage effect of pioglitazone in the
human studies reported by Belfort et al and Lutchman et
al [17,28]. Our result provided evidence that retrieval of
mitochondrial antioxidant defense mechanism by piogli-
tazone may explain another therapeutic mechanism of
TZD for NAFLD.
Conclusion
Our study clearly demonstrated that there was signifi-
cantly increased oxidative stress and oxidative DNA dam-
age in steatotic livers of a mice model fed with a high fat
diet. The oxidative DNA damage induced by a high fat diet
can be attenuated by pioglitazone treatment through up-
regulation of the antioxidant defense and oxidative DNA
repair genes (Sod1, Sod2, Ogg1 and MutY).
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